The landscape of functional foods—known in China as 保健食品 (bǎojiàn shípǐn)—has long been governed by a dual-track system of 注册 (zhùcè) for new ingredients and 备案 (bèi’àn) for established formulas. However, recent changes to the 保健食品注册与备案管理办法 (Bǎojiàn Shípǐn Zhùcè yǔ Bèi’àn Guǎnlǐ Bànfǎ), or the Functional Food Registration and Filing Management Measures, are reshaping how foreign and domestic companies bring products to market.
This update provides a concise, data-driven analysis of the current approval pipeline, the regulatory shifts driving it, and what foreign executives must prioritize to capitalize on the $72 billion Chinese functional food market.
The State of the Pipeline: Volume and Velocity
Through the first three quarters of 2024, SAMR and its provincial equivalents have processed 1,892 new registrations and 4,350 filing applications. The combined total of 6,242 submissions represents a 22% year-over-year increase in overall activity.
Approval times have also shifted. While full registrations for novel ingredients still require an average of 17 months, streamlined filing for established formulas (e.g., vitamins, minerals, probiotics) now takes just 42 working days in major provinces like Guangdong and Zhejiang.
The backlog of pending applications has decreased by 12% since January 2024, thanks to the digitization of the 国家市场监督管理总局 (Guójiā Shìchǎng Jiāndū Guǎnlǐ Zǒngjú) online portal. However, applications with incomplete toxicology or stability data still face rejection rates of 21%.
For foreign companies, the key bottleneck remains the requirement for onshore clinical trials for any product claiming a new functional benefit—a process that adds an average of 8–12 months to the timeline.
Regulatory Priorities: What the Regulator is Watching
SAMR’s 2024 enforcement priorities focus on three areas: immunity claims, child-specific labeling, and the use of new raw materials. Products targeting 增强免疫力 (zēngqiáng miǎnyìlì), or immunity enhancement, comprise 34% of all new filings—the largest single category.
The regulator has also tightened standards for 功能性食品 (gōngnéngxìng shípǐn) marketed to children under 14 years, requiring separate safety assessments and lower maximum dosage limits for 12 active ingredients, including zinc and melatonin.
In a notable shift, SAMR has approved 14 new raw materials for functional food use in 2024, including 燕窝肽 (yànwō tài) (edible bird’s nest peptide) and GABA (γ-氨基丁酸, Gamma-aminobutyric acid) for sleep health. These additions open new formulation possibilities for foreign brands that can secure a domestic manufacturing partner.
China’s “Clean Label” movement, driven by the 国民营养计划 (Guómín Yíngyǎng Jìhuà) or National Nutrition Plan, is also pushing the regulator to demand full disclosure of excipients and additives. Products with artificial colors or high sugar content now face longer review cycles.
Table: China Functional Food Approval Statistics (2023–2024)
| Metric | 2023 | 2024 (Q1–Q3) | Change |
|---|---|---|---|
| New registration applications | 2,171 | 1,892 | +31% (annualized) |
| Filing applications processed | 4,210 | 4,350 | +22% |
| Average registration time (months) | 18.5 | 17.0 | −8% |
| Approved new raw materials | 9 | 14 | +56% |
| Rejection rate (incomplete data) | 24% | 21% | −3 pp |
| Immunity-related applications share | 29% | 34% | +5 pp |
Source: SAMR public data and industry reports, compiled by China Gateway 360. 2024 figures are through September 30 and annualized for comparison.
Category Trends: Where the Growth is Concentrated
Beyond immunity, three categories are driving the bulk of new filings. 肠道健康 (chángdào jiànkāng), or gut health, accounts for 19% of applications, with probiotics and prebiotic fibers leading the way. The market for probiotic-based functional foods in China is projected to reach $14.6 billion by 2026.
Beauty-from-within products—known locally as 美容保健食品 (měiróng bǎojiàn shípǐn)—represent 16% of new filings. Collagen peptides, hyaluronic acid, and astaxanthin are the most commonly submitted ingredients, with the segment growing at 27% annually.
Sleep and stress management products, categorized under 改善睡眠 (gǎishàn shuìmián), account for 12% of new registrations. Melatonin, GABA, and L-theanine blends are the typical formulations, but SAMR has flagged concerns about over-dosing, leading to stricter maximum limits in 2024.
Energy and sports nutrition, or 运动营养 (yùndòng yíngyǎng), is a smaller but fast-growing segment at 8% of new filings. This category benefits from China’s growing fitness culture and the 2025 National Fitness Plan, which is driving demand for protein bars, electrolyte drinks, and pre-workout formulas.
For foreign brands, the most accessible entry point remains the filing track for established ingredients. Products that use only ingredients on the 保健食品原料目录 (Bǎojiàn Shípǐn Yuánliào Mùlù), or the Functional Food Raw Materials Catalogue, can bypass full registration and reach market in as little as 6 weeks after filing approval.
Key Risks and Delays in the Approval Process
Despite the acceleration in processing times, several recurring issues continue to delay approvals. The most common reason for rejection—accounting for 34% of all denials—is inadequate stability data under China-specific storage conditions, particularly for products containing live probiotics.
Labeling compliance is the second-largest source of rejection at 28%. SAMR enforces strict rules on font sizes, mandatory disclaimers, and the placement of the 保健食品标志 (bǎojiàn shípǐn biāozhì), or the “Blue Hat” logo. Any deviation can trigger a return to the queue.
Foreign companies also face challenges with ingredient sourcing documentation. SAMR now requires full traceability from raw material origin through to finished product, with notarized certificates for any ingredient sourced outside China. This has tripled documentation preparation time for imported formulations.
Cross-border e-commerce (CBEC) remains a faster but more limited alternative. Products sold through CBEC channels do not require SAMR registration, but they are restricted to the 跨境电子商务零售进口商品清单 (Kuàjìng Diànzǐ Shāngwù Língshòu Jìnkǒu Shāngpǐn Qīngdān), or the Cross-border E-commerce Retail Import List. This list covers only 86 functional food categories, excluding many novel ingredients.
NEXT STEPS: 3 Decision-Path Recommendations
-
Path A: Fast-Track Filing for Established Ingredients. If your product uses only ingredients on the Functional Food Raw Materials Catalogue—such as vitamins, minerals, probiotics, or approved botanicals—pursue the filing track in a pilot province like Guangdong or Hainan. This route can achieve market entry in 6–10 weeks. Read our guide to the filing track process »
-
Path B: Full Registration for Novel Functional Claims. For products with new ingredients or proprietary health claims, budget for a 17–24 month timeline and factor in the cost of a local clinical trial partner. Start raw material documentation and stability testing at least 3 months before submission. View our registration timeline template »
-
Path C: CBEC Pilot for Market Testing. If you are unsure about long-term commitment, launch through cross-border e-commerce on Tmall Global or JD Worldwide. This allows you to test demand without full SAMR registration, but limits you to the 86 approved categories. Plan to transition to full registration within 18 months. Compare CBEC vs. registration costs »
The functional food approval pipeline in China is moving faster than it has in years, but the window for easy entry is narrowing. As SAMR continues to raise safety and documentation standards, companies that invest early in compliance infrastructure will have a lasting advantage over those that delay.
Whether your strategy is to file now or test via CBEC first, the key is to partner with a regulatory consultant who understands the nuances of local clinical data requirements and the evolving raw materials catalogue. China’s functional food market rewards speed, but it penalizes shortcuts.
